| Name | ICRF |
|---|---|
| Synonyms | ICRF; P19; PSP; PTP; Islet cells regeneration factor; Islet of Langerhans regenerating protein; Lithostathine 1 alpha; Lithostathine 1 alpha precursor… |
| Name | anthraquinone |
|---|---|
| CAS | 9,10-anthracenedione |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 8930764 | Cummings J, Meikle I, Macpherson JS, Smyth JF: Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Oct 11;685(1):159-64. A high-performance liquid chromatographic technique is presented for the determination of the novel topoisomerase I inhibitor NU/ICRF 505 (a conjugate of anthraquinone), its major metabolite (NU/ICRF 505/M) and an internal standard (NU/ICRF 513, conjugate). |
85(1,1,1,5) | Details |
| 8765530 | Cummings J, Meikle I, Macpherson JS, Smyth JF: Characterization of the major metabolite of the novel topoisomerase I inhibitor NU/ICRF 505. Anticancer Drug Des. 1996 Jul;11(5):367-82. NU/ICRF 505 is a conjugate of anthraquinone modified at the C terminus of the amino acid as an ethyl ester and it stabilizes topoisomerase I (topo I)-cleavable complexes. |
87(1,1,1,7) | Details |
| 14679008 | Cummings J, Ethell BT, Jardine L, Boyd G, Macpherson JS, Burchell B, Smyth JF, Jodrell DI: Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res. 2003 Dec 1;63(23):8443-50. Identification of the UGT responsible for glucuronidation of SN-38 and the anthraquinone NU/ICRF 505 was achieved by first using a panel of human cDNA-expressed isozymes to measure conjugating activity. |
81(1,1,1,1) | Details |
| 11992628 | Cummings J, Boyd G, Ethell BT, Macpherson JS, Burchell B, Smyth JF, Jodrell DI: Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem Pharmacol. 2002 Feb 15;63(4):607-13. As part of a program to identify novel mechanisms of resistance to topoisomerase I (topo I) inhibitors, the cellular pharmacology of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of clinically used irinotecan (CPT-11) and NU/ICRF 505, an anthraquinone- conjugate, has been investigated in two human colorectal cancer (CRC) cell lines. |
35(0,1,1,5) | Details |
| 7598737 | Meikle I, Cummings J, Macpherson JS, Hadfield JA, Smyth JF: Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates. Biochem Pharmacol. 1995 Jun 16;49(12):1747-57. Mono-conjugation of an anthraquinone nucleus with a range of naturally occurring amino acids chemically modified at their C-terminus has been adopted as a synthetic approach in the rational design of novel topoisomerase (topo) inhibitors. The biochemistry of topo I and II inhibition has been investigated for a series of 16 new compounds (NU/ICRF 500-515) from which structure-activity relationships have been investigated. |
6(0,0,0,6) | Details |
| 8913431 | Cummings J, Hadfield JA, Meikle I, McGown AT, Smyth JF: Molecular modeling of the interaction of anthracenyl-amino acid topoisomerase inhibitors with the DNA sequence d (CGTACG). Anticancer Drugs. 1996 Aug;7(6):636-41. Modeling data were in good agreement with physical data showing that five compounds intercalated DNA with the anthraquinone chromophore orientated in parallel to the long dimension of the d (CpG) base pairs and the amino acid placed in the minor groove. The amino acid chain of the topo I inhibitor (NU/ICRF 600, gly-phe) extended significantly out from the helical axis horizontal. |
2(0,0,0,2) | Details |